15 Dec 2022 12:50 CET

Issuer

GENTIAN DIAGNOSTICS ASA

Moss, 15 December 2022

Reference is made to the annual general meeting 18 May 2022 where a statement of
remuneration to key personnel was given. In accordance with this statement the
board of Gentian Diagnostics ASA has allocated a total of 219,996 options to key
employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 80,000 options. Following the allocations
Ms. Ibert holds 6,525 shares and 359,924 options

Njaal Kind, Group Chief Financial Officer: 19,996 options. Following the
allocations Mr. Kind holds 21,125 shares and 175,666 options in the Company.

Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation
Mr. Knüttel holds 1,125 shares and 40,000 options in the Company.

Jack Andreassen, Vice President Business Development: 10,000 options. Following
the allocation Mr. Andreassen hold 4,385 shares and 32,500 options in the
Company.

Markus Jaquemar, Vice President Sales and Marketing: 25,000 options. Following
the allocation Mr. Jaquemar holds 47,500 options in the Company.

The exercise price for the options granted is NOK 46,67 being the average
volume-weighted share price on the Oslo Stock Exchange from 1 January 2022 to 13
December 2022. The right to exercise the options is vested over a period of 2
years, with 50% of the options vesting by the end of each year as follows: (i)
50% of the options granted, no earlier than 3 years after the allocation date
(ii) 50% of the options granted, no earlier than 4 years after the allocation
date.

Attached are the notifications of the transactions pursuant to the market abuse
regulation article 19.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525


578263_2022 Notification forms options.pdf

Source

Gentian Diagnostics ASA

Provider

Oslo Børs Newspoint

Company Name

GENTIAN DIAGNOSTICS ASA

ISIN

NO0010748866

Symbol

GENT

Market

Oslo Børs